Industry News
Mesoblast progressing towards Phase 3 trial bone marrow trial in US
Regenerative medicine specialists Mesoblast today announced that it has provided market guidance to the FDA regarding its Phase 3 bone marrow transplantation program, which it hopes will create more options for patients as well as a reduction in incidences of graft-versus-host disease (GVHD). [ + ]
Feature: Xenotransplantation offers hope to diabetes sufferers
Back when Living Cell Technologies's (LCT) current Medical Director and Founder, Professor Bob Elliott, was working in his Auckland clinic, he decided that the treatments available for patients with Type I diabetes simply weren't good enough. [ + ]
Garvan researchers overturn T cell “dogma”
Researchers from Sydney's Garvan Institute have challenged the dominant view in immunology circles as to how a special type of immune cell, called a T follicular helper cell (Tfh), is generated. [ + ]
Market report: ASX holds firm despite global gloom
The Australian stock market ended slightly up today as miners helped the bourse to resist to drag of poor performers such as Telstra, although it wasn’t enough to continue the run of five consecutive weekly gains. [ + ]
UK study shows single neurons can think for themselves
British researchers have shown that individual neurons are capable of processing far more complex information than traditionally thought. [ + ]
Monash names Professor Scott O’Neill as new science Dean
Monash University has announced the appointment of esteemed Australian scientist and medical researcher Professor Scott O’Neill as the University’s new Dean of Science. [ + ]
BioTech Capital throws in the towel
BioTech Capital One, of the highest profile Australian biotech investment funds announced on Thursday that it will no longer pursue new opportunities in the sector and will liquidate its current investment portfolio, returning the proceeds to shareholders. [ + ]
AQL and Farmacule merger complete
The merger of private therapeutic protein and biofuels company Farmacule and publicly-listed industrial algae specialists AquaCarotene (AQL) was completed yesterday creating a promising new Australian biotechnology company producing biofuels and plant-made compounds for use in the medical research, nutraceutical and industrial markets. [ + ]
Labor science policy has little new for life sciences
The federal Labor party reached out for the science vote today with the announcement of its Science for Australia’s Future policy, although there’s little there explicitly for life sciences or the biotechnology industry. [ + ]
Help from the dark side
Using 'dark channel' fluorescence, scientists can explain how biochemical substances carry out their function.
[ + ]Monash appoints Dean for Faculty of Science
Monash University has announced the appointment of biologist Professor Scott O’Neill to the position of Dean, Faculty of Science.
[ + ]First child stem cell trachea transplant a success
An 11-year old Irish boy has become the world’s first child to receive a transplant of a new trachea grown from his own stem cells, the BBC has reported. [ + ]
Market report: ASX chalks up five-week winning streak
The Australian stock market finished the week up for the fifth week in a row today as investor’s maintained their run of confidence despite weaker-than-expected jobs and retail sales data out of the US overnight. [ + ]
Common sea sponge may yield clues to early cell development
It’s not normally something that would inspire scuba divers to do a double take, but a species of sponge commonly found on the Great Barrier Reef has researchers all in a lather at the prospect of learning about the genesis of cell behaviour. [ + ]
Study links full-fat dairy with reduced heart attack risk
In yet another case of conventional medical wisdom being turned on its head, researchers at the Queensland Institute of Medical Research (QIMR) have completed a study showing that people who consume full-fat dairy may have a lower risk of heart attack. [ + ]
